The FORCETM Platform Leverages TfR1 to Deliver Functional Improvement in the Clinic
1:30 pm - Monday 23rd February 2026
- Exploring the FORCETM modular drug delivery approach to enable widespread distribution of AOCs and chemically diverse therapeutic payloads to muscle and the CNS
- Assessing clinical data from DYNE-101 ACHIEVE trial in patients with DM1 and DYNE-251 DELIVER trial against DMD
- Contextualising how the encouraging clinical data and preclinical efficacy in FSHD and Pompe models supports the potential of FORCETM and AOCs to address neuromuscular disorders with high unmet medical needs